BioCardia® Receives US Patent Covering a Method of Producing Mesenchymal Stem Cells Using a Single Patient Donor for Both Source Cells and Culture Medium

May 09, 2016

SAN CARLOS, CABioCardia®, Inc., a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, with clinical programs in heart failure and sub-acute infarction, today announced the issuance of United States Patent No. 9,301,975 relating to a method of producing cells cultured in media derived from a single human donor. 

Dr. Peter Altman, CEO of BioCardia:  “We are pleased to have obtained this new patent.  To our knowledge, this is the first patent covering a method of producing mesenchymal cells from a single donor for cells and culture medium.  This contributes to the more than 75 issued patents related to cardiovascular regenerative medicine to which BioCardia has either exclusive or nonexclusive rights.”

Dr. Eric Duckers, CMO of BioCardia:  “This may open new pathways for allogenic dosage forms that address the problems of expansion of cells to enable large numbers of patients to be treated, lot to lot variability of culture media, and immune responses to allogenic cells.  The patent specification also contains details on the use of transcriptome wide gene expression profiling for the development of companion diagnostics for autologous cell based therapies to maximize the probability of clinical success.”

About BioCardia®
BioCardia, Inc., headquartered in San Carlos, CA is a privately held company developing regenerative biologic therapies to treat cardiovascular disease. The Company's current products include the Helix™ transendocardial delivery system and the Morph® steerable guide and sheath catheter portfolio. BioCardia partners with other biotherapeutic companies to provide its Helix systems and clinical support to their programs studying therapies for the treatment of heart failure, chronic myocardial ischemia and acute myocardial infarction.

Miranda Peto Benvenuti | 650-226-0120


Have questions?
: (800) 624-1179
Have questions?

biocardia takes a new and comprehensive
approach to heart failure

By introducing patient screening and highly-efficient delivery to stem cell therapy, the company seeks to increase the likelihood of treatment success, enabling more patients to return to the things they love.